SCHEMBL3089993

SCHEMBL3089993

Nc1ccc(-c2ccccn2)cc1C1=CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.50
TDP1 Q9NUW8 1/20 0.42
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PI4KA P42356 1/20 0.39
PIK3CG P48736 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
PTGS2 P35354 1/20 0.39
CHEK2 O96017 1/20 0.38
HDAC1 Q13547 4/20 0.38
HDAC2 Q92769 4/20 0.38
HDAC3 O15379 2/20 0.38
CYP1A2 P05177 1/20 0.36
GRM5 P41594 1/20 0.36
FFAR2 O15552 1/20 0.35
PDK2 Q15119 1/20 0.35
F2RL1 P55085 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089990 0.82 CSF1R (0.53) CSF1RTDP1PTGS2CHEK2GRM5
SCHEMBL3096089 0.80 PTGS2 (0.43) CSF1RTDP1PTGS2HDAC1HDAC2
SCHEMBL16387219 0.80 HDAC2 (0.52) PTGS2HDAC1HDAC2HDAC3
SCHEMBL3083133 0.78 KDR (0.48) CSF1RPTGS2HDAC1HDAC2HDAC3
SCHEMBL7071127 0.76 TDP1 (0.56) CSF1RTDP1CYP1A2GRM5
SCHEMBL30374920 0.76 TDP1 (0.56) CSF1RTDP1CYP1A2GRM5
SCHEMBL3083333 0.76 CYP11B1 (0.50) CSF1RPIK3CDPIK3CAPI4KAPI4KB
SCHEMBL3096261 0.76 CSF1R (0.46) CSF1RTDP1PTGS2HDAC1HDAC2
SCHEMBL3086559 0.76 CSF1R (0.53) CSF1RTDP1PIK3CDHDAC1HDAC2
SCHEMBL15583348 0.76 PTGS2 (0.43) CSF1RTDP1PTGS2HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885TDP1 1739/4885PIK3CD 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.